Literature DB >> 9688058

Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate).

C Passirani1, G Barratt, J P Devissaguet, D Labarre.   

Abstract

PURPOSE: In a biomimetic approach to the development of drug carriers escaping early capture by phagocytes, nanoparticles made of amphiphilic copolymers of either heparin or dextran and methyl methacrylate were evaluated relative to their in vivo blood circulation time. They were compared to bare PMMA nanoparticles.
METHODS: Owing to the fluorescent properties of the covalently attached N-vinyl carbazole, the particles could be detected directly in mouse plasma. Samples were drawn at different time intervals and fluorescence was recorded.
RESULTS: After an initial phase of elimination from the blood with a half-life of 5 h, the remaining heparin nanoparticles circulated for more than 48 h and were still detectable in the plasma at 72 h. Dextran nanoparticles were also eliminated very slowly over 48 h. Bare poly (methyl methacrylate) nanoparticles were found to have a half-life of only 3 min.
CONCLUSIONS: Both types of nanoparticles proved to be long-circulating. The potent capacity for opsonisation of the poly(methyl methacrylate) core were hidden by the protective effect of either polysaccharide, probably due to a dense brush-like structure. In the case of heparin nanoparticles, the "stealth" effect was probably increased by its inhibiting properties against complement activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9688058     DOI: 10.1023/a:1011930127562

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

Review 1.  Anti-inflammatory effects of heparin and its derivatives: inhibition of complement and of lymphocyte migration.

Authors:  H P Ekre; Y Naparstek; O Lider; P Hydén; O Hägermark; T Nilsson; I Vlodavsky; I Cohen
Journal:  Adv Exp Med Biol       Date:  1992       Impact factor: 2.622

Review 2.  Surface modification with functionally active heparin.

Authors:  J Riesenfeld; P Olsson; J Sanchez; T E Mollnes
Journal:  Med Device Technol       Date:  1995-03

3.  Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles.

Authors:  M T Peracchia; C Vauthier; C Passirani; P Couvreur; D Labarre
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

4.  Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators.

Authors:  M Vittaz; D Bazile; G Spenlehauer; T Verrecchia; M Veillard; F Puisieux; D Labarre
Journal:  Biomaterials       Date:  1996-08       Impact factor: 12.479

5.  Intraocular PMMA lenses modified with surface-immobilized heparin: evaluation of biocompatibility in vitro and in vivo.

Authors:  R Larsson; G Selén; H Björdklund; P Fagerholm
Journal:  Biomaterials       Date:  1989-10       Impact factor: 12.479

6.  Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system.

Authors:  C Passirani; G Barratt; J P Devissaguet; D Labarre
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

7.  Specific antibodies enhance Sephadex-induced activation of the alternative complement pathway in human serum.

Authors:  M P Carreno; F Maillet; D Labarre; M Jozefowicz; M D Kazatchkine
Journal:  Biomaterials       Date:  1988-11       Impact factor: 12.479

8.  Interactions of poly(lactic acid) and poly(lactic acid-co-ethylene oxide) nanoparticles with the plasma factors of the coagulation system.

Authors:  H Sahli; J Tapon-Bretaudière; A M Fischer; C Sternberg; G Spenlehauer; T Verrecchia; D Labarre
Journal:  Biomaterials       Date:  1997-02       Impact factor: 12.479

9.  Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b.

Authors:  F Maillet; M D Kazatchkine; D Glotz; E Fischer; M Rowe
Journal:  Mol Immunol       Date:  1983-12       Impact factor: 4.407

10.  The ability of Sephadex to activate human complement is suppressed in specifically substituted functional Sephadex derivatives.

Authors:  M P Carreno; D Labarre; M Jozefowicz; M D Kazatchkine
Journal:  Mol Immunol       Date:  1988-02       Impact factor: 4.407

View more
  24 in total

Review 1.  Strategies in the design of nanoparticles for therapeutic applications.

Authors:  Robby A Petros; Joseph M DeSimone
Journal:  Nat Rev Drug Discov       Date:  2010-07-09       Impact factor: 84.694

Review 2.  Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis.

Authors:  Morteza Mahmoudi; Mohammad A Sahraian; Mohammad A Shokrgozar; Sophie Laurent
Journal:  ACS Chem Neurosci       Date:  2011-02-04       Impact factor: 4.418

Review 3.  Methods for the preparation and manufacture of polymeric nanoparticles.

Authors:  Christine Vauthier; Kawthar Bouchemal
Journal:  Pharm Res       Date:  2008-12-24       Impact factor: 4.200

Review 4.  Engineering antiphagocytic biomimetic drug carriers.

Authors:  Alicia Sawdon; Ching-An Peng
Journal:  Ther Deliv       Date:  2013-07

5.  Evaluation of new bi-functional terpolymeric nanoparticles for simultaneous in vivo optical imaging and chemotherapy of breast cancer.

Authors:  Alireza Shalviri; Ping Cai; Andrew M Rauth; Jeffery T Henderson; Xiao Yu Wu
Journal:  Drug Deliv Transl Res       Date:  2012-12       Impact factor: 4.617

Review 6.  Application of polysaccharides for surface modification of nanomedicines.

Authors:  Kyung-Oh Doh; Yoon Yeo
Journal:  Ther Deliv       Date:  2012-12

7.  New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma.

Authors:  Henri de Martimprey; Jean-Rémi Bertrand; Claude Malvy; Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2010-01-20       Impact factor: 4.200

8.  Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles.

Authors:  Cédric Chauvierre; Denis Labarre; Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

Review 9.  Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.

Authors:  Qi Yang; Christina L Parker; Justin D McCallen; Samuel K Lai
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

10.  Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers.

Authors:  Archibald Paillard; Catherine Passirani; Patrick Saulnier; Maya Kroubi; Emmanuel Garcion; Jean-Pierre Benoît; Didier Betbeder
Journal:  Pharm Res       Date:  2009-10-23       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.